Clinical Trial Update: Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Brentuximab Vedotin in elderly patients with Hodgkin Lymphoma at first relapse or with primary refractory disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED